403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
US Checkpoint Therapeutics obtains USD58m in funding
(MENAFN) Checkpoint Therapeutics, Inc., the New York based immuno-oncology Biopharmaceutical Company has secured a fund totaling at USD58 million, according to the latest reports.
Accordingly, officials at Checkpoint stressed that the raised cash has marked an important progress for the firm and will be directed at the acceleration of its drug development pipeline.
Checkpoint Therapeutics focuses on the acquisition, development, and commercialization of targeted immune-enhanced combination treatments for patients with solid tumor cancers.
"We plan to use the proceeds from the financing to advance our portfolio of antibodies and our small molecule inhibitor of epidermal growth factor receptor (EGFR) mutations," said the firm's CEO.
Accordingly, officials at Checkpoint stressed that the raised cash has marked an important progress for the firm and will be directed at the acceleration of its drug development pipeline.
Checkpoint Therapeutics focuses on the acquisition, development, and commercialization of targeted immune-enhanced combination treatments for patients with solid tumor cancers.
"We plan to use the proceeds from the financing to advance our portfolio of antibodies and our small molecule inhibitor of epidermal growth factor receptor (EGFR) mutations," said the firm's CEO.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment